KOSPIHolding Companies002620

Jeil Pharma Holdings

₩6,700▼ 4.29%2026-11-18 close
Market Cap
₩107B
Turnover
₩17,475,840
Volume
2.6K
Shares out.
16M
PER
42.5×
PBR
0.3×
EPS
₩159
Dividend Yield
1.04%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩70 per share · Prices as of the 2026-11-18 close

01

Report overview

Two Straight Loss Quarters After 2025 Turnaround; Holding-Discount Test Ahead

Operating profit returned to the black in 2025, but two consecutive operating loss quarters from Q2 2026 put the durability of subsidiary profitability in focus.

  1. 1

    Operating profit of KRW 38.7 billion in 2025 turned positive, while revenue fell for a second straight year to KRW 657.6 billion.

  2. 2

    Operating losses of KRW 9.94 billion in Q2 2026 and KRW 3.4 billion in Q3 2026 extended the loss run to two straight quarters.

  3. 3

    Net income attributable to controlling shareholders was KRW 14.6 billion in 2025, but the last four quarters total only KRW 2.53 billion.

  4. 4

    Own-product growth around zastaprazan and lower cost ratios are cited as the core of the 2025 recovery.

  5. 5

    Whether the PBR and payout ratio targets in the value-enhancement plan voluntarily disclosed in October 2026 are met in subsequent earnings and dividend disclosures is the next point to check.

02

Business structure

Jeil Pharma Holdings, founded in 1959 and listed in 1988, has operated as a holding company since its 2017 spin-off. It runs no production plants; its income comes from investment returns, brand fees, management consulting fees and the management of its subsidiaries.

The core subsidiary, Jeil Pharmaceutical, is held at a 49.2% stake, and Jeil Pharmaceutical in turn holds 44.05% of a drug-discovery subsidiary. The OTC subsidiary (92.4% stake) sells non-prescription drugs, and its flagship patch product entered Daiso stores in 2024.

The 100%-owned sales agency handles contract sales for Jeil Pharmaceutical and can also sell other pharmaceutical companies' products. In product terms, the acid-reflux drug zastaprazan, a P-CAB, launched in 2024 and anchors the shift toward own products.

In a deal signed in March 2023, Jeil Pharmaceutical granted Livzon Pharmaceutical Group exclusive development and sales rights in China, Taiwan, Hong Kong and Macau, with an upfront fee of USD 15 million. As of September 10, 2026, the largest shareholder group held 73.21% and Otsuka Pharmaceutical held 9.37%.

Investment real estate accounts for 44.7% of standalone total assets, according to company statements. Jeil Pharmaceutical's 2025 consolidated revenue was KRW 567.2 billion, with operating profit of KRW 20.7 billion and net income of KRW 32.0 billion.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩161.4B₩18.1B11.2%
2025Q4₩154.4B₩6.6B4.2%
2026Q1₩150.4B₩3.6B2.4%
2026Q2₩164.7B-₩9.9B−6.0%
2026Q3₩156.7B-₩3.4B−2.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩793B-₩7.5B-₩83.1B−1.0%−24.6%106.2%
2023₩804B₩20.8B-₩13.2B2.6%−4.1%118.8%
2024₩779.8B-₩11.6B-₩66.4B−1.5%−21.6%103.6%
2025₩657.6B₩38.7B₩14.6B5.9%4.6%86.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 793 billion in 2022 to KRW 804 billion in 2023 (up 1.4% year on year), then fell to KRW 779.8 billion in 2024 (down 3.0%) and KRW 657.6 billion in 2025 (down 15.7%), a two-year decline from 2024 through 2025. Among 2022 to 2025, 2023 was the largest year and 2025 the smallest.

Operating results moved from an operating loss of KRW 7.55 billion in 2022 to operating profit of KRW 20.8 billion in 2023 (a turn to profit), an operating loss of KRW 11.6 billion in 2024 (a turn to loss), and operating profit of KRW 38.7 billion in 2025 (a turn to profit).

Operating margins were -1.0%, 2.6%, -1.5% and 5.9%.

Net income attributable to controlling shareholders was a loss of KRW 83.1 billion in 2022, a loss of KRW 13.2 billion in 2023 (losses continued but narrowed), a loss of KRW 66.4 billion in 2024 (losses continued and widened), and income of KRW 14.6 billion in 2025 (a turn to profit).

The 2025 net income of KRW 34.6 billion differs from the controlling-shareholder figure because it includes non-controlling interests. The company said 2024 carried a one-time cost from impairment of a subsidiary, while 2025 had no such impairment factor, which improved results.

The recovery was led by better profitability and streamlined operations at Jeil Pharmaceutical, with a higher share of own products and a lower cost ratio. The debt ratio fell from 106.2% in 2022 to 118.8% in 2023, 103.6% in 2024 and 86.9% in 2025.

At the end of 2025, total equity was KRW 469.1 billion, of which KRW 318.7 billion belonged to controlling shareholders, and total liabilities were KRW 407.5 billion. Operating cash flow went from -KRW 20.8 billion in 2022 and -KRW 4.42 billion in 2023 to KRW 4.54 billion in 2024 and KRW 390 million in 2025.

Quarterly, operating profit fell from KRW 18.1 billion in Q3 2025 to KRW 6.55 billion in Q4 2025 (down 63.8% from the prior quarter) and KRW 3.56 billion in Q1 2026 (down 45.7%). Q2 2026 revenue rose 9.5% quarter on quarter to KRW 164.7 billion, yet the company posted an operating loss of KRW 9.94 billion.

Q3 2026 revenue was KRW 156.7 billion (down 2.9% year on year) with an operating loss of KRW 3.4 billion. Net income attributable to controlling shareholders over the last four quarters totals KRW 2.53 billion.

05

Industry analysis

The pharmaceutical industry is in a phase of intensifying competition. Analysts point to the entry of multinational companies, large domestic conglomerates entering pharma, and wider investment in cGMP facilities as raising competitive intensity.

Prescription drug demand has grown, but more generic launches have led to earnings declines across the sector. In this structure, a holding company's results track its subsidiaries directly, so it absorbs the sector cycle in full.

The company cites its shift away from a merchandise-led model toward own products and lower cost ratios as drivers of the profitability recovery. Reports say the cost of sales ratio fell from 78.3% in 2022 to 59.3% at the end of the first half of 2026.

The cost improvement shows the strategy in numbers, but revenue shrank over the same period, so whether the cost gains offset the smaller sales base is the key question. On policy, an October 2026 article said the financial regulator was about to publish its first list of low-PBR companies.

The company attributed its low PBR at the end of 2025 to weak profitability and thin trading volume. The comparison here stays within the structural differences of the business.

06

Outlook

In a voluntary disclosure on October 22, 2026, the company set a 2028 target of a 0.5x PBR and a 20% dividend payout ratio. The plan centers on Jeil Pharmaceutical and on turning zastaprazan growth and a product-led business mix into earnings gains.

Jeil Pharmaceutical plans to expand own-product sales around zastaprazan and raise operating profit through better production and investment efficiency. The company also plans to reflect follow-on drug development at its drug-discovery subsidiary in its medium-term value.

It is reviewing use of 622,230 treasury shares, equal to 3.9% of issued shares as of end-June 2026, but has not set out a disposal method or cancellation schedule. Recovery at the OTC subsidiary, a review of investment real estate, and expanded IR for institutional investors and analysts were also listed as tasks.

At the March 2026 general meeting, the company said it would focus on streamlining its business structure and managing risk. A reorganization announced in late March 2026 created a management support division and promoted subsidiary executives.

The 59.3% cost ratio is cited as evidence of margin improvement, but revenue declined over the same period, so the pace of sales recovery is the next checkpoint. An external tally showed first-half 2026 revenue down 7.8% year on year. Whether the operating loss pattern continues in the 2026 annual report is the key item to confirm.

07

Valuation

PER
42.5×
PBR
0.3×
ROE
0.8%
EPS
₩159
BPS
₩20,355
Dividend per share
₩70

The share price trades well below book value per share. The company attributes the persistent discount to weak profitability and thin trading volume, and its 2028 target of a 0.5x PBR sits above the current level.

An October 2026 article expected that reaching a valuation in line with net asset value will take considerable time. Earnings-based multiples are sensitive to earnings swings, because net income attributable to controlling shareholders over the last four quarters totals only KRW 2.53 billion.

The 2025 turn to profit put annual earnings back in positive territory, but two straight loss quarters from Q2 2026 mean multiple readings depend on the quarterly trend. The board approved a cash dividend on common shares, and the target payout ratio is 20%.

Because the disposal method and cancellation schedule for treasury shares have not been set, they remain a variable in per-share value.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Shift Toward Zastaprazan and Own Products

The company says a move away from a merchandise-led model, with more own products and better cost ratios, is reflected in the profitability recovery. Reports say the cost of sales ratio at Jeil Pharmaceutical fell from 78.3% in 2022 to 59.3% at the end of the first half of 2026.

If zastaprazan sales keep growing, the share of own products and operating margins could rise together. The consolidated operating margin recovered from -1.5% in 2024 to 5.9% in 2025.

2025 Turn to Profit and Earnings Recovery

Operating profit in 2025 was KRW 38.7 billion, turning from an operating loss of KRW 11.6 billion in 2024. Net income of KRW 34.6 billion reversed the prior year's net loss. Net income attributable to controlling shareholders was KRW 14.6 billion, a turn to profit from a loss of KRW 66.4 billion in 2024. The company cites the absence of the 2024 one-time impairment cost as a driver of the improvement.

Value-Enhancement Plan and Treasury Shares

The company disclosed a voluntary value-enhancement plan in October 2026 with a 2028 target of a 0.5x PBR and a 20% payout ratio. Treasury shares stood at 622,230 as of end-June 2026, or 3.9% of issued shares.

No disposal method or cancellation schedule has been set, though the company has stated it will use treasury shares to enhance value. If the plan is carried out, shareholder returns could rise independently of earnings.

09

Bear factors

Loss Quarters Resume in 2026

The Q2 2026 operating loss of KRW 9.94 billion turned a profitable Q1 into a loss. Q3 narrowed the loss to KRW 3.4 billion, but that still makes two straight loss quarters. Net losses attributable to controlling shareholders were KRW 3.55 billion in Q2 and KRW 2.33 billion in Q3. An external tally showed first-half 2026 consolidated revenue down 7.8% year on year.

Intensifying Competition from Generics

Industry commentary points to intensifying competition from multinational entrants, large domestic groups entering pharma, and heavier cGMP investment. Even as prescription drug demand grows, more generic launches have weakened earnings across the sector.

Because results are concentrated in one core subsidiary, the holding company absorbs this pressure directly. Whether cost gains alone can sustain the recovery while revenue shrinks remains an open question.

Persistent Discount to Net Assets

The company attributed its low PBR to weak profitability and thin trading volume. Commentary says the distance to its 0.5x PBR target is still considerable. With 44.7% of standalone total assets in investment real estate, the asset mix could also be cited as a discount factor. One analysis warns the company could face weaker negotiating positions in any sale or outside investment.

10

Risk factors

Uncertain Returns on Drug Development

The company acknowledged that drug development has required heavy spending without yet delivering visible results. Own-product growth leans heavily on one product, so earnings volatility persists until follow-on pipeline results emerge. Results at the drug-discovery subsidiary also affect consolidated and equity-method earnings.

Recurrence of Subsidiary Impairment

In 2024 an impairment at a subsidiary added a one-time cost that worsened results. The company said 2025 had no such impairment trigger, which improved earnings. If subsidiary profitability weakens again, a similar impairment could recur and increase volatility in consolidated earnings. The risk becomes closer if the 2026 loss pattern continues.

Thin Float and Concentrated Ownership

The largest shareholder group holds 73.21%, which limits the shares available for trading. The free float ratio was reported at about 22.89% as of September 2026. Thin trading volume has been cited as a discount factor.

Because the disposal method for treasury shares has not been set, the impact on supply and demand is hard to gauge.

11

What to watch next

  1. Around March 31, 2027 (statutory deadline for the annual report)

    The 2026 annual report will confirm full-year operating results and Q4 2026 figures. How the loss pattern since Q2 2026 is reflected on an annual basis is the next checkpoint.

  2. Around March 2027 (estimated from the March 24, 2026 meeting date)

    The annual general meeting will show whether dividends and any treasury-share disposal or cancellation are on the agenda. It is the first point at which progress toward the 20% payout target becomes visible.

  3. Around May 15, 2027 (statutory deadline for the Q1 quarterly report)

    Whether Q1 2027 operating results move out of loss, and whether own-product mix and the cost ratio trend hold, are the items to check.

  4. Timing not yet set

    A disclosure on disposal or cancellation of the 622,230 treasury shares will fix the method and share count, and it directly affects the number of shares in circulation.

12

Overall view

Jeil Pharma Holdings is a holding company whose consolidated results depend heavily on subsidiary Jeil Pharmaceutical. Revenue fell for a second straight year in 2025 to KRW 657.6 billion, but operating profit turned to KRW 38.7 billion as own-product mix and cost ratios improved.

Operating losses then appeared from Q2 2026, producing two straight loss quarters, and net income attributable to controlling shareholders over the last four quarters totals KRW 2.53 billion.

Bullish factors include the zastaprazan-led product shift, the 2025 earnings improvement, and the value-enhancement plan with treasury-share review. Bearish factors include the 2026 loss pattern, intensifying generic-driven competition, and a persistent discount to net assets.

Drug development returns and the risk of subsidiary impairment recurring add to earnings volatility. The next checkpoints are how the 2026 annual report presents full-year operating results and the Q4 trend, and whether Q1 2027 moves out of loss. Progress toward the 0.5x PBR and 20% payout targets for 2028 is the medium-term item to track.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. kind.krx.co.kr
  2. businesspost.co.kr
  3. etoday.co.kr
  4. comp.wisereport.co.kr
  5. m.news.nate.com
  6. dailypharm.com
  7. news.nate.com
  8. view.asiae.co.kr
  9. pflow.keywordegg.com
  10. m.news.nate.com
  11. m.news.nate.com
  12. accidentalorder.com
  13. asiatime.co.kr
  14. news.nate.com
  15. judal.co.kr
  16. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis